Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$33.55M+33.94%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yuling Luo
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 308
- Beta
- -6.18
- Country
- US
Financials
ALMR has only 4 quarterly periods on file — the charts below show the full history available.
Revenue
$33.55M+33.9%Net Income
$-13.34MEBITDA
$-13.10MFree Cash Flow
$-15.20MEPS (diluted)
$-0.19Shares Outstanding (diluted)
69.11M+1.8%Operating Expenses
$35.78MCash & Debt
$226.59MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $74.21M | $-29.82M | $-0.45 |
Valuation
ALMRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60+20.00%Social Signal Score
Mentions (12)
- Newsfool.com·5h ago·Positive
Alamar Biosciences: 3 Key Takeaways for Long-Term Investors Full-year 2026 revenue guidance increased to $121 million -- $123 million. U.K. Biobank selected NULISA to profile 80,000 samples for neurodegenerative markers.
View source ↗ - Newsglobenewswire.com·2d ago·Neutral
JAMA Study Using Alamar Biosciences' NULISA Assay Links Blood eMTBR-tau to Tau tangle Burden in Former Football Players with Advanced CTE FREMONT, Calif., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced new research published in the Journal of the American Medical Association (JAMA).
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Alamar Biosciences to Participate in Upcoming Investor Conferences Fremont, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be participating in the following investor conferences:
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Alamar Biosciences, Inc. (ALMR) Q3 2026 Earnings Call Transcript Alamar Biosciences, Inc. (ALMR) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
Alamar Biosciences Q3 Earnings Call Highlights Alamar Biosciences NASDAQ: ALMR reported third-quarter revenue growth of 68% year over year, driven by rising consumables sales, new instrument placements and its largest Technology Access Program, or TAP, services quarter to date. The precision proteomics company also raised its full-year revenue outlook and highlighted newly announced large-scale collaborations with UK Biobank and GSK.
View source ↗ - Newszacks.com·19d ago·Neutral
Alamar (ALMR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Alamar (ALMR) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newsglobenewswire.com·25d ago·Positive
Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology Published in Nature Communications, the study found a 10-protein signature that outperformed a leading individual ALS biomarker, including in some patients with difficult-to-diagnose presentations Published in Nature Communications, the study found a 10-protein signature that outperformed a leading individual ALS biomarker, including in some patients with difficult-to-diagnose presentati
View source ↗ - Newsglobenewswire.com·59d ago·Neutral
Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab
View source ↗ - Newsseekingalpha.com·98d ago·Positive
…h Alamar Biosciences' ARGO instruments automate NULISA assays. This creates a platform that can convert placements into recurring consumables' demand. I concede that ALMR's broader disease panels and sampling could also deepen the utilization of its platform and expand its long-term TAM even into diagnostics. The good news is that consumables are growing faster than instruments. But we need to see if this will be long-term profitable growth as the installed base expands.
View source ↗ - Newsseekingalpha.com·100d ago·Positive
…nue grew 82% YoY to $29.4M, with consumables sales up 147% and gross margin rising to 60%, highlighting improving revenue quality and operational leverage potential. ALMR's installed base enables capital-efficient expansion, with new assays deployable across existing instruments, creating workflow stickiness and recurring revenue opportunities.
View source ↗ - Newsseekingalpha.com·104d ago·Positive
Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·104d ago·Neutral
Alamar Biosciences Q2 Earnings Call Highlights Alamar Biosciences NASDAQ: ALMR reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company's first earnings call since completing its April initial public offering.
View source ↗
Earnings
Tue, Feb 2(in 2 months)
Consensus estimate $-0.28 per share
Typical surprise +5.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$-0.19 vs $-0.20beat
- Mon, Aug 10$-0.22 vs $-0.31beat
- Fri, May 8$-1.74 vs $-1.71miss
Estimates and results for ALMR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALMR officers and directors.
- Bought
- —
- Sold
- $36.3m
0 trades
92 trades
- Qiming Corporate Gp Vi, Ltd.sold
- Qiming Corporate Gp Vi, Ltd.sold
- Qiming Corporate Gp Vi, Ltd.sold
- Qiming Corporate Gp Vi, Ltd.sold
- Qiming Corporate Gp Vi, Ltd.sold
- Qiming Corporate Gp Vi, Ltd.sold
- Qiming Corporate Gp Vi, Ltd.sold
- Qiming Corporate Gp Vi, Ltd.sold
8 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ALMR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
